Business
Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
HOUSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing
About this update from Marker Therapeutics, Inc.
[{"type":"text","content":"HOUSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan F. Vera, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference, which is being held on September 11-13, 2023 at the Lotte New York Palace Hotel in New York City. Dr. Vera will provide an overview of Marker’s advancements and clinical development programs on Wednesday, September 13, 2023, at 8:30 a.m. EDT. Of note, Marker believes its therapies are superior to CAR T cells because Marker’s therapies use cancer killing T cells that are not genetically engineered and have more ways to recognize cancer cells than what is possible with current CAR T cell therapies. During the conference, Dr. Vera and members of Marker will conduct one-on-one meetings with registered investors. Details of the presentation are as follows: Event:H.C. Wainwright 25th Annual Global Investment ConferenceDate & Time:September 13, 2023 at 8:30 AM, EDTLocation:Kennedy IWebcast Link:https://journey.ct.events/view/5f505fae-5fbc-4a22-964d-59232c33372d The presentation will be available for replay starting September 14, 2023 on the Investors & Media section of Marker’s website. About Marker Therapeutics, Inc.Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The cell therapy technology Marker has in place is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e., tumor targets) and kill tumor cells expressing those targets. This population of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer the T cells, Marker believes that its product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered CAR-T and TCR-based approaches, and may provide ...